3,10-dihydroxy-2-naphthacene Carboxamide Or Derivative (e.g., Tetracycline, Etc.) Doai Patents (Class 514/152)
  • Patent number: 10883976
    Abstract: Methods of preparing compositions for preferential distribution of active agents to injury sites are provided. The compositions may comprise a polymer with hydrophilic properties and one or more active agents, such as compounds comprising hydrophilic metal ions. Because the delivery ligand and the active agent are specifically selected so the interactions between them are mainly of an ionic nature. Methods of identifying suitable components for such compositions are also disclosed.
    Type: Grant
    Filed: February 12, 2015
    Date of Patent: January 5, 2021
    Assignee: Warsaw Orthopedic, Inc.
    Inventors: Josee Roy, Victor Kelley, Roger E. Harrington
  • Patent number: 10874632
    Abstract: The present disclosure targets the Zika virus and other disease-causing microbes including viruses, bacteria, fungi, and parasites. It does this using agents and methods with little toxicity compared to existing therapies.
    Type: Grant
    Filed: February 18, 2020
    Date of Patent: December 29, 2020
    Inventor: Steven Baranowitz
  • Patent number: 10842802
    Abstract: The present disclosure provides novel controlled release pharmaceutical dosage form, methods of making the same, and methods of using the same to treat dermatological conditions.
    Type: Grant
    Filed: May 8, 2013
    Date of Patent: November 24, 2020
    Assignee: MEDICIS PHARMACEUTICAL CORPORATION
    Inventors: Sajeev Chandran, Shirishkumar Kulkarni, Pravin Meghrajji Bhutada, Ashish Ashokrao Deshmukh, Douglas Bakan, Mitchell Wortzman
  • Patent number: 10835613
    Abstract: The present disclosure relates generally to compositions for cosmetic or pharmaceutical application. The compositions include a carrier and rheology modulators.
    Type: Grant
    Filed: April 17, 2019
    Date of Patent: November 17, 2020
    Assignee: Foamix Pharmaceuticals Ltd.
    Inventors: Dov Tamarkin, Elana Gazal, Yohan Hazot, David Schuz, Irakliy Papiashvili
  • Patent number: 10821187
    Abstract: The present disclosure relates generally to compositions for cosmetic or pharmaceutical application. The compositions include a carrier and rheology modulators.
    Type: Grant
    Filed: February 20, 2019
    Date of Patent: November 3, 2020
    Assignee: Foamix Pharmaceuticals Ltd.
    Inventors: Dov Tamarkin, Elana Gazal, Yohan Hazot, David Schuz, Irakliy Papiashvili
  • Patent number: 10603299
    Abstract: The present disclosure targets the Zika virus and other disease-causing microbes including viruses, bacteria, fungi, and parasites. It does this using agents and methods with little toxicity compared to existing therapies.
    Type: Grant
    Filed: July 3, 2019
    Date of Patent: March 31, 2020
    Inventor: Steven Baranowitz
  • Patent number: 10543298
    Abstract: A tetracycline salt comprising a tetracycline and an organic acid wherein the organic acid is oxalic acid or maleic acid is provided. The tetracycline is preferably doxycycline, minocycline, sancycline, lymecycline, tetracycline or demeclocycline, and preferred salts include oxycycline maleate, minocycline oxalate, tetracycline oxalate, demeclocycline maleate, demeclocycline oxalate, sancycline maleate, lymecycline maleate, or lymecycline oxalate. A pharmaceutical formulation comprising a tetracycline salt according to the invention is also provided, as is a medical device having coated thereon a salt or pharmaceutical formulation according to the invention. A salt of the invention, or a formulation of the invention are also provided for use as medicaments, particularly for use in the treatment or prevention of an inflammation and/or an infection.
    Type: Grant
    Filed: November 24, 2016
    Date of Patent: January 28, 2020
    Assignee: Hovione Scientia Limited
    Inventors: Luis Sobral, Livia Santana De Arruda, Margarida Figueiredo, Rafael Antunes, Ana Paula Filipe
  • Patent number: 10493163
    Abstract: The present invention provides dendrimer conjugates. The present invention provides a composition comprising a dendrimer conjugate and a cell, such as a cell covered with dendrimer conjugates, in which dendrimer conjugates home the cell to a target tissue.
    Type: Grant
    Filed: June 30, 2017
    Date of Patent: December 3, 2019
    Assignee: UNIVERSITY OF MIAMI
    Inventors: Omaida Velazquez, Sylvia Daunert, Pirouz Daftarian, Zhao-Jun Liu, Sapna Deo
  • Patent number: 10383852
    Abstract: The present invention targets the Zika virus and other disease-causing microbes including viruses, bacteria, fungi, and parasites. It does this using agents and methods with little toxicity compared to existing therapies.
    Type: Grant
    Filed: November 27, 2018
    Date of Patent: August 20, 2019
    Inventor: Steven Baranowitz
  • Patent number: 10385003
    Abstract: Disclosed herein is an ophthalmic formulation comprising a compound of formula (I): wherein R1 is a linear or branched C9-C33 alkyl or a linear or branched C9-C33 alkenyl with 1 to 4 double bonds; R2 is a linear or branched C9-C19 alkyl or a linear or branched C9-C19 alkenyl with 1 to 4 double bonds; and an ophthalmologically acceptable carrier.
    Type: Grant
    Filed: December 21, 2012
    Date of Patent: August 20, 2019
    Inventors: Thomas Millar, Burkhardt Schuett
  • Patent number: 10383884
    Abstract: The invention disclosed herein provides a method for treating Community-Acquired Bacterial Pneumonia (CABP) using 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline or a salt thereof, in either oral or IV doses or a combination of both.
    Type: Grant
    Filed: October 31, 2017
    Date of Patent: August 20, 2019
    Assignee: Paratek Pharmaceuticals, Inc.
    Inventors: Evangelos L. Tzanis, Paul McGovern, Amy L. Manley, Lynne Garrity-Ryan, S. Ken Tanaka
  • Patent number: 10314912
    Abstract: Described herein are coating compositions for consumer and/or medical products. The coating compositions can be used to confer desirable properties to the consumer and/or medical products.
    Type: Grant
    Filed: March 13, 2017
    Date of Patent: June 11, 2019
    Assignee: Ariste Medical, LLC
    Inventors: Lisa Jennings, Jonathan McCanless, Brian Best, Timothy Fabian, Michael Cole
  • Patent number: 10314926
    Abstract: The present invention relates to methods and compositions for treating, ameliorating or preventing a disease or disorder in a subject by introducing into cells of the subject a therapeutic gene switch construct that controls expression of one or more therapeutic products.
    Type: Grant
    Filed: June 29, 2017
    Date of Patent: June 11, 2019
    Assignee: Intrexon Corporation
    Inventors: Bethany Lynn Merenick, Robert P. Beech, Thomas D. Reed, Anna P. Tretiakova, Richard E. Peterson
  • Patent number: 10273468
    Abstract: The present disclosure provides compositions and methods for treating bacterial infections in a subject. The methods comprise administering a compound that binds a FAD-dependent flavoenzyme and a tetracycline, analog, derivative, or pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: June 26, 2017
    Date of Patent: April 30, 2019
    Assignee: Washington University
    Inventors: Niraj Tolia, Gautam Dantas, Timothy Wencewicz, Jooyoung Park, Andrew Gasparrini, Kevin Forsberg, Joseph Vogel, Margaret Ruth Reck, Chanez Tiffany Symister, Jana L. Markley
  • Patent number: 10238670
    Abstract: The invention disclosed herein provides a method for treating urinary tract infection (UTI) using 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline or a salt thereof, in either oral or IV doses or a combination of both.
    Type: Grant
    Filed: May 2, 2017
    Date of Patent: March 26, 2019
    Assignee: Paratek Pharmaceuticals, Inc.
    Inventors: Amy L. Manley, Evangelos L. Tzanis, Lynne Garrity-Ryan, S. Ken Tanaka, Judith N. Steenbergen, Stephen Bai
  • Patent number: 10159685
    Abstract: The invention relates to the use of a poly(ADP ribose) polymerase (PARP) inhibitor and/or a tetracycline, for treating, preventing or ameliorating medial vascular calcification, and to pharmaceutical compositions comprising PARP inhibitors or tetracycline.
    Type: Grant
    Filed: June 15, 2017
    Date of Patent: December 25, 2018
    Assignees: Cambridge Enterprise Limited, King's College London
    Inventors: Melinda Duer, David Reid, Catherine Shanahan
  • Patent number: 10124066
    Abstract: In one aspect, the invention provides a stabilized lipid-based glycopeptide antibiotic composition and a process for producing the same. In another aspect, the invention provides methods for treating a bacterial pulmonary infection by administering to a subject in need thereof a therapeutically effective amount of the stabilized lipid-based glycopeptide antibiotic composition.
    Type: Grant
    Filed: November 27, 2013
    Date of Patent: November 13, 2018
    Assignee: INSMED INCORPORATED
    Inventors: Walter Perkins, Vladimir Malinin
  • Patent number: 10124014
    Abstract: Methods and compositions for using a tetracycline compound to treat bacterial infections are described. In one embodiment, for example, the invention provides a method of treating a subject for an infection, comprising administering to said subject an effective amount of 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline or a salt thereof, such that said subject is treated, wherein said infection is selected from the group consisting of MSSA, MRSA, B-streptococci, Viridans Streptococci, Enterococcus, or combinations thereof.
    Type: Grant
    Filed: June 29, 2017
    Date of Patent: November 13, 2018
    Assignee: Paratek Pharmaceuticals, Inc.
    Inventors: Sean M. Johnston, Robert D. Arbeit, Thomas J. Bigger, Dennis P. Molnar, S. Ken Tanaka
  • Patent number: 10111890
    Abstract: Methods and compositions for using a tetracycline compound to treat bacterial infections are described. In one embodiment, for example, the invention provides a method of treating a subject for an infection, comprising administering to said subject an effective amount of 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline or a salt thereof, such that said subject is treated, wherein the 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline is administered orally at a dose of about 450 mg per day for two consecutive days, then at a dose of about 300 mg per day for 5 or more days.
    Type: Grant
    Filed: August 3, 2017
    Date of Patent: October 30, 2018
    Assignee: Paratek Pharmaceuticals, Inc.
    Inventors: S. Ken Tanaka, Evangelos L. Tzanis, Lynne Garrity-Ryan, Amy L. Manley
  • Patent number: 10065924
    Abstract: In one aspect, the present invention provides novel derivatives of viridicatumtoxin of the formula wherein the variables are as defined herein. The application also provides compositions, methods of treatment, and methods of synthesis thereof.
    Type: Grant
    Filed: July 22, 2015
    Date of Patent: September 4, 2018
    Assignee: WILLIAM MARSH RICE UNIVERSITY
    Inventors: Kyriacos C Nicolaou, Christopher R. H. Hale, Christian Nilewski, Heraklidia Ioannidou, Abdellatif El Marrouni
  • Patent number: 9775855
    Abstract: The present invention provides for methods, compositions, and kits pertaining to the treatment of various diseases associated with inflammation. In various aspects, the invention provides methods and compositions comprising an effective amount of a macrolide and an effective amount of a tetracycline.
    Type: Grant
    Filed: September 13, 2012
    Date of Patent: October 3, 2017
    Inventors: Thomas J. Lewis, Clement L. Trempe
  • Patent number: 9724430
    Abstract: The present invention relates to methods and compositions for treating, ameliorating or preventing a disease or disorder in a subject by introducing into cells of the subject a therapeutic gene switch construct that controls expression of one or more therapeutic products.
    Type: Grant
    Filed: September 24, 2015
    Date of Patent: August 8, 2017
    Assignee: Intrexon Corporation
    Inventors: Bethany Lynn Merenick, Robert P. Beech, Thomas D. Reed, Anna P. Tretiakova, Richard E. Peterson
  • Patent number: 9724358
    Abstract: Methods and compositions for using a tetracycline compound to treat bacterial infections are described. In one embodiment, for example, the invention provides a method of treating a subject for an infection, comprising administering to said subject an effective amount of 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline or a salt thereof, such that said subject is treated, wherein said infection is selected from the group consisting of MSSA, MRSA, B-streptococci, Viridans Streptococci, Enterococcus, or combinations thereof.
    Type: Grant
    Filed: February 2, 2016
    Date of Patent: August 8, 2017
    Assignee: Paratek Pharmaceuticals, Inc.
    Inventors: Sean M. Johnston, Robert D. Arbeit, Thomas J. Bigger, Dennis P. Molnar, S. Ken Tanaka
  • Patent number: 9700574
    Abstract: The invention relates to the combination of secnidazole with an antibiotic of the macrolide family, preferably azithromycin 11, for oral treatment of dental infections, which enables a considerable reduction in the length of treatment and the doses administered in comparison with the conventional treatment.
    Type: Grant
    Filed: May 14, 2012
    Date of Patent: July 11, 2017
    Assignee: ATHENA PHARMACEUTIQUES SAS
    Inventor: Pierre-Marie Defrance
  • Patent number: 9657090
    Abstract: The invention provides a method of treating alveolar bone loss involving administration of a sclerostin inhibitor to a subject in need thereof.
    Type: Grant
    Filed: December 11, 2012
    Date of Patent: May 23, 2017
    Assignees: AMGEN INC., THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Hua Zhu Ke, Min Liu, William V. Giannobile
  • Patent number: 9624166
    Abstract: The present invention is directed to a compound represented by Structural Formula (1): or a pharmaceutically acceptable salt thereof. The variables for Structural Formula (I) are defined herein. Also described is a pharmaceutical composition comprising the compound of Structural Formula (I) and its therapeutic use.
    Type: Grant
    Filed: August 27, 2010
    Date of Patent: April 18, 2017
    Assignee: Tetraphase Pharmaceuticals, Inc.
    Inventors: Yonghong Deng, Louis Plamondon, Cuixiang Sun, Xiao-Yi Xiao, Jingye Zhou, Joyce A. Sutcliffe, Magnus P. Ronn
  • Patent number: 9605175
    Abstract: Described herein are coating compositions for consumer and/or medical products. The coating compositions can be used to confer desirable properties to the consumer and/or medical products.
    Type: Grant
    Filed: October 29, 2013
    Date of Patent: March 28, 2017
    Assignee: ARISTE MEDICAL, LLC
    Inventors: Lisa Jennings, Jonathan McCanless, Brian Best, Timothy Fabian, Michael Cole
  • Patent number: 9562003
    Abstract: A method for modulating RNA with tetracycline compounds is described.
    Type: Grant
    Filed: July 2, 2015
    Date of Patent: February 7, 2017
    Assignee: Paratek Pharmaceuticals, Inc.
    Inventors: Stuart B. Levy, Michael P. Draper, Mark L. Nelson, Graham Jones
  • Patent number: 9532996
    Abstract: Doxycycline formulations with a reduced food effect are disclosed. Particularly disclosed are modified release formulations which can be administered once a day and exhibit a reduced food effect. Methods of treating inflammatory conductions such as rosacea or inflammatory symptoms such as the papules and pustules of rosacea or acne vulgaris are also disclosed.
    Type: Grant
    Filed: November 19, 2015
    Date of Patent: January 3, 2017
    Assignee: Dr. Reddy's Laboratories Ltd.
    Inventors: Ankit Baheti, Bijay Kumar Padhi, Rajeev Singh Raghuvanshi
  • Patent number: 9481639
    Abstract: Methods and compositions for the treatment of skin disorders (e.g., acne, rosacea) are described.
    Type: Grant
    Filed: August 19, 2013
    Date of Patent: November 1, 2016
    Assignee: Paratek Pharmaceuticals, Inc.
    Inventors: Haregewein Assefa, Beena Bhatia, Michael P. Draper, Laura Honeyman, Oak K. Kim, Dennis P. Molnar
  • Patent number: 9365500
    Abstract: The present invention pertains, at least in part, to novel 9-substituted minocycline compounds. These minocycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for minocycline and minocycline compounds in general, such as blocking tetracycline efflux and modulation of gene expression.
    Type: Grant
    Filed: June 27, 2014
    Date of Patent: June 14, 2016
    Assignee: PARATEK PHARMACEUTICALS, INC.
    Inventors: Mark L. Nelson, Roger Frechette, Mohamed Y. Ismail, Laura Honeyman, Todd Bowser, Beena Bhatia
  • Patent number: 9365499
    Abstract: The present invention relates to 9-aminomethyl substituted tetracycline compounds represented by formula (I), or pharmaceutically acceptable salt, prodrug, solvate or isomer thereof, as well as a method for preparing these compounds and a pharmaceutical composition comprising the same. The present invention relates also to a use of these compounds in the preparation of a medicament for the treatment and/or prophylaxis of tetracycline drug-sensitive disease. wherein, R2a, R2b, R3, R4a, R4b, R5, R6a, R6b, R7, R8, R9a, R9b, R10, R11, R12, R13a and R13b are each independently as defined in the description.
    Type: Grant
    Filed: July 26, 2012
    Date of Patent: June 14, 2016
    Assignee: KBP Biosciences Co., Ltd.
    Inventors: Hui Zhang, Yanyan Dong
  • Patent number: 9333261
    Abstract: The present invention provides a novel therapeutic combination comprising one or more anti-androgen agents and one or more antibiotic/anti-inflammatory agents or pharmaceutically acceptable salts or hydrates thereof, useful for the treatment of a dermatological disorder.
    Type: Grant
    Filed: January 17, 2014
    Date of Patent: May 10, 2016
    Assignee: M. ALPHABET 1, LLC
    Inventors: Howard Fein, Mindy B. Berlin
  • Patent number: 9327015
    Abstract: A method of correcting spinal deformity, which includes locating pharmaceutical-loaded implants adjacent to targeted spinal growth plates, and then eluting the pharmaceutical onto the growth plates. Preferably, the method involves correcting spinal deformity by simply inserting a pharmaceutical-eluting pedicle screw onto the concave side of a scoliotic curve. In some embodiments, the screw has a cannulated internal reservoir that contains a growth-inhibiting pharmaceutical (such as a tetracycline) and at least one fenestration that allows the pharmaceutical to elute onto the vertebral body growth plate.
    Type: Grant
    Filed: March 24, 2010
    Date of Patent: May 3, 2016
    Assignee: DePuy Synthes Products, Inc.
    Inventors: Hassan Serhan, Michael J. O'Neil, Sean Lilienfeld, Thomas M. DiMauro
  • Patent number: 9278105
    Abstract: The present invention relates to compositions, pharmaceutical compositions, and methods for preparing the same, comprising a tetracycline with improved stability and solubility. Some embodiments include a tetracycline with an excess of a divalent or trivalent cation.
    Type: Grant
    Filed: October 17, 2012
    Date of Patent: March 8, 2016
    Assignee: Rempex Pharmaceuticals, Inc.
    Inventors: David C. Griffith, Serge Boyer, Michael N. Dudley, Scott Hecker
  • Patent number: 9278911
    Abstract: The present invention pertains, at least in part, to novel substituted 4-dedimethylamino tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for minocycline and tetracycline compounds in general, such as blocking tetracycline efflux and modulation of gene expression.
    Type: Grant
    Filed: February 10, 2014
    Date of Patent: March 8, 2016
    Assignee: Paratek Pharmaceuticals, Inc.
    Inventors: Mark L. Nelson, Kwasi Ohemeng
  • Patent number: 9278079
    Abstract: An ocular composition consisting essentially of purified water, PEG-80 sorbitan laurate, sodium trideceth sulfate, PEG-150 distearate, sodium lauroamphoacetate, cocamidopropyl hydroxysultaine, sodium laureth-13 carboxylate, sodium chloride, PEG-15 cocopolyamine, polyhexamethylene biguanide, potassium sorbate, 1,2 hexanediol, and caprylyl glycol. The composition can be applied to a fabric pad for use as an eyelid cleanser, where the fabric pad is pre-moistened with the composition and packaged for use. The composition may also be used in an eyelid treatment kit for convenient combination treatments to improve overall eyelid hygiene and adjunctive eyelid therapy.
    Type: Grant
    Filed: July 12, 2013
    Date of Patent: March 8, 2016
    Assignee: OCuSOFT, Inc.
    Inventors: Nat Adkins, Jr., Cynthia Barratt
  • Patent number: 9265740
    Abstract: Methods and compositions for using a tetracycline compound to treat bacterial infections are described. In one embodiment, for example, the invention provides a method of treating a subject for an infection, comprising administering to said subject an effective amount of 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline or a salt thereof, such that said subject is treated, wherein said infection is selected from the group consisting of MSSA, MRSA, B-streptococci, Viridans Streptococci, Enterococcus, or combinations thereof.
    Type: Grant
    Filed: April 22, 2014
    Date of Patent: February 23, 2016
    Assignee: Paratek Pharmaceuticals, Inc.-124418
    Inventors: Sean M. Johnston, Robert D. Arbeit, Thomas J. Bigger, Dennis P. Molnar, S. Ken Tanaka
  • Patent number: 9260550
    Abstract: In an example, a process for the production of an acrylate polymer is disclosed. The process includes reacting lactide with a bromination material to form a brominated lactide. The process further includes reacting the brominated lactide with an elimination material to form an acrylic monomer, and polymerizing the acrylic monomer to form an acrylate polymer.
    Type: Grant
    Filed: January 27, 2015
    Date of Patent: February 16, 2016
    Assignee: INTERNATIONAL BUSINESS MACHINES CORPORATION
    Inventors: Dylan J. Boday, Timothy C. Mauldin
  • Patent number: 9255139
    Abstract: The present invention relates to fusion constructs of glycosylphosphatidylinositol (GPI)-anchored tissue inhibitors of metalloproteinases (TIMPs) and their use for the treatment of cancer and in regenerative medicine. By this approach, the GPI-anchored TIMP proteins are incorporated into the surface membrane of tumor cells and render tumor cells sensitive to FAS-induced apoptosis. Furthermore, the fusion constructs of the present invention are effective agents useful in wound healing applications. In one embodiment, the TIMP is linked to mucin followed by GPI in order to enhance surface presentation. The use of GPI to link TIMP renders the resulting fusion protein particularly useful as an anti-cancer agent for the treatment of cancer, and, in particular, any residual cancer following an incomplete surgical resection of primary tumors in an individual.
    Type: Grant
    Filed: September 20, 2006
    Date of Patent: February 9, 2016
    Inventors: Ralf Huss, Peter J. Nelson
  • Patent number: 9211296
    Abstract: This invention provides methods of inhibiting replication of a poxvirus by contacting a poxvirus with a compound having formula I, formula XXI, formula XXXII, or formula XLI which in turn reduce, inhibit, or abrogate poxvirus DNA polymerase activity and/or its interaction with its processivity factor. Formula I, formula XXI, formula XXXII, or formula XLI can be utilized to treat humans and animals suffering from a poxvirus infection. Pharmaceutical compositions for treating poxvirus infected subjects are also provided.
    Type: Grant
    Filed: August 27, 2013
    Date of Patent: December 15, 2015
    Assignee: The Trustees of the University of Pennsylvania
    Inventor: Robert P. Ricciardi
  • Patent number: 9084802
    Abstract: The present invention relates to compositions, pharmaceutical compositions, and methods for preparing the same, comprising a tetracycline with improved stability and solubility. Some embodiments include a tetracycline with an excess of a divalent or trivalent cation.
    Type: Grant
    Filed: March 11, 2014
    Date of Patent: July 21, 2015
    Assignee: REMPEX PHARMACEUTICALS, INC.
    Inventors: David C. Griffith, Serge Boyer, Scott Hecker, Michael N. Dudley
  • Patent number: 9080012
    Abstract: The instant disclosure describes a ring opening polymerization (ROP) of cyclic monomer components using a nucleophilic transesterification catalyst system in a neat, single pot reaction to obtain homopolymers and copolymers.
    Type: Grant
    Filed: July 10, 2013
    Date of Patent: July 14, 2015
    Assignee: Xerox Corporation
    Inventors: Valerie M Farrugia, Andrew J Myles, Karen A Moffat, Jordan H Wosnick
  • Publication number: 20150148317
    Abstract: A drug delivery system is provided for treatment of oxidative stress. The drug delivery system can include a therapeutic agent and a matrix. The therapeutic agent can include an antioxidant or steroid. The matrix can include a hydrogel, particle, microparticle, or nanoparticle. A method of treating injury, including peripheral nerve injury or spinal cord injury, is also provided. The method includes injecting the drug delivery system at the site of injury.
    Type: Application
    Filed: November 26, 2014
    Publication date: May 28, 2015
    Applicants: InVivo Therapeutics Corporation, Massachusetts Institute of Technology
    Inventors: Christopher D. Pritchard, Robert S. Langer, Francis M. Reynolds, Eric J. Woodard
  • Publication number: 20150140073
    Abstract: Drug delivery compositions are disclosed that include multimolecular assemblies that have heparosan polymer(s) attached thereto and therapeutic(s) (and/or potential therapeutic(s)) entrapped, carried, or otherwise bound in the multimolecular assemblies. Methods for producing and using the drug delivery compositions are also disclosed.
    Type: Application
    Filed: January 28, 2015
    Publication date: May 21, 2015
    Inventor: Paul L. DeAngelis
  • Publication number: 20150141350
    Abstract: A nanodevice composition including N-acetyl cysteine linked to a dendrimer, such as a PAMAM dendrimer or a multiarm PEG polymer, is provided. Also provided is a nanodevice for targeted delivery of a compound to a location in need of treatment. The nanodevice includes a PAMAM dendrimer or multiarm PEG polymer, linked to the compound via a disulfide bond. There is provided a nanodevice composition for localizing and delivering therapeutically active agents, the nanodevice includes a PAMAM dendrimer or multiarm PEG polymer and at least one therapeutically active agent attached to the PAMAM dendrimer or multiarm PEG polymer.
    Type: Application
    Filed: September 4, 2014
    Publication date: May 21, 2015
    Inventors: Rangaramanujam M. Kannan, Sujatha Kannan, Roberto Romero, Raghavendra S. Navath, Hui Dai, Anupa R. Menjoge
  • Publication number: 20150139946
    Abstract: Provided is a method for monitoring a gene mutation associated with a cancer in a patient over time. Also provided is a method of selecting and/or applying treatment or therapy for a subject.
    Type: Application
    Filed: October 19, 2014
    Publication date: May 21, 2015
    Inventors: Mark G. Erlander, Karena Kosco, Cecile Rose Vibat
  • Publication number: 20150141381
    Abstract: Methods and compounds for treating diseases with tetracycline compounds having a target therapeutic activity are described.
    Type: Application
    Filed: May 22, 2014
    Publication date: May 21, 2015
    Applicant: Paratek Pharmaceuticals, Inc.
    Inventors: Stuart B. Levy, Michael P. Draper, Mark L. Nelson, Graham Jones
  • Publication number: 20150132343
    Abstract: A method of treating a patient, comprising administering at least one antibiotic, e.g., doxycycline and ciprofloxacin, sufficient to substantially treat an intracellular bacterial organism present in at least erythrocytes, e.g., over a course of at least two weeks; and subsequently administering at least one immunostimulant, e.g., which directly or indirectly increases levels of immunostimulatory cytokines in the patient, and at least one antioxidant, e.g., glutathione, to effectively treat a coinfection of the patient with a virus. The intracellular bacterial organism may be a rickettsiales-like organism, and the virus may be HIV.
    Type: Application
    Filed: November 10, 2014
    Publication date: May 14, 2015
    Inventor: Luc Montagnier
  • Publication number: 20150125496
    Abstract: The present application provides a dosage form and related methods for making the dosage form. The dosage form generally comprises a hydrophilic active ingredient, a plurality of solid, porous microcarriers, each having a hydrophobic surface, an optional hydrophobic encapsulant, and a hydrophilic delivery agent, wherein (i) the hydrophilic active ingredient is associated with the plurality of solid, porous microcarriers, (ii) the plurality of solid, porous microcarriers is encapsulated by the hydrophobic encapsulant, and (iii) the hydrophilic delivery agent is physically separated from a majority of the hydrophilic active ingredient by a boundary between the hydrophilic delivery agent and the hydrophobic encapsulant. In some embodiments, the dosage form is for topical application. In some additional embodiments, the plurality of solid, porous microcarriers is formed by modifying the microcarriers to increase their hydrophobicity.
    Type: Application
    Filed: November 4, 2014
    Publication date: May 7, 2015
    Inventor: Akira Yamamoto